{"Clinical Trial ID": "NCT03098550", "Intervention": ["INTERVENTION 1:", "Nivolumab + Daratumumab (TBT)", "* Trinegative breast cancer (TBT) treated with trinegative breast cancer (TBT) treated with Nivolumab IV 240 mg Q2W (weeks 3-24) + Daratumumab IV 16 mg/kg Q1W (weeks 1-8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)", "INTERVENTION 2:", "Nivolumab + Daratumumab (NSCLC)", "* Non-small cell lung cancer (NCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3-24) + Daratumumab IV 16 mg/kg Q1W (weeks 1-8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)"], "Eligibility": ["Incorporation criteria:", "For more information on participation in Bristol-Myers Squibb clinical trials, please visit www.BMSSstudyConnect.com.", "Patients with metastatic or advanced solid tumours", "Women with triple negative breast cancer confirmed histologically or cytologically", "Participants with histologically or cytologically confirmed pancreatic adenocarcinoma", "Participants with non-small cell lung cancer confirmed by histology or cytology (NCSLC)", "- Exclusion criteria:", "Active brain metastases or leptomeningal metastases.", "Any serious or uncontrolled medical condition", "A previous malignancy active in the previous 3 years", "Other inclusion/exclusion criteria defined by the Protocol may apply."], "Results": ["Performance measures:", "Number of participants with adverse reactions (ARs)", "Number of participants with adverse reactions (ADRs) classified according to common terminology criteria for adverse reactions (CTCAE v4.0) to determine the safety and safety of Nivolumab and Daratumumab", "Time: from the first dose to 30 days after the last dose (up to 34 months)", "Results 1:", "Title of arm/group: Nivolumab + Daratumumab (TNCB)", "Description of the arm/group: Trinegative breast cancer (TBT) treated with trinegative breast cancer (TBT) treated with Nivolumab IV 240 mg Q2W (weeks 3-24) + Daratumumab IV 16 mg/kg Q1W (weeks 1-8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)", "Total number of participants analysed: 41", "Type of measure: Number of participants", "Unit of measure: Participants 41 100.0%", "Results 2:", "Title of arm/group: Nivolumab + Daratumumab (NSCLC)", "Description of the arm/group: Non-small cell lung cancer (NCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3-24) + Daratumumab IV 16 mg/kg Q1W (weeks 1-8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)", "Total number of participants analysed: 21", "Type of measure: Number of participants", "Unit of measure: Participants 21 100.0%"], "Adverse Events": ["Undesirable Events 1:", "Total: 36/41 (87.80 per cent)", "Anemia 0/41 (0.00 %)", "1/41 (2.44 per cent)", "Acute coronary syndrome 0/41 (0.00 %)", "Atrial fibrillation 0/41 (0.00 %)", "Cardiac Tapponade 1/41 (2.44%)", "- Cardiorespiratory arrest 0/41 (0.00 %)", "Pericardial infusion 0/41 (0.00 %)", "Abdominal pain 0/41 (0.00 %)", "- Collision 0/41 (0.00 per cent)", "Diarrhoea 0/41 (0.00 %)", "Adverse Events 2:", "Total: 17/21 (80.95 per cent)", "Anemia 0/21 (0.00 %)", "Febrile bone marrow aplasia 0/21 (0.00 %)", "Acute coronary syndrome 1/21 (4.76%)", "Atrial fibrillation 0/21 (0.00 %)", "- Cardiac Tapponade 0/21 (0.00 %)", "- Cardiorespiratory arrest 0/21 (0.00 %)", "1/21 (4.76%)", "Abdominal pain 0/21 (0.00 %)", "Colite 1/21 (4.76 per cent)", "Diarrhoea 1/21 (4.76%)"]}